tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BeOne Medicines price target raised to $330 from $313 at Morgan Stanley

Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $330 from $313 and keeps an Overweight rating on the shares following the R&D day that highlighted the company’s pipeline programs. Management is targeting a 2026 approval for Sonrotoclax and 2027 approval for BGB16673, notes the analyst, who contends that Street estimates for BGB-16673 and Sonrotoclax are “too conservative.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1